Owners, management and financials
CVR: 33964870
EUR 6,958,825
Gross profit
Net result: EUR -2,299,046
CHR. OLESEN A/S (50-66,65%), Signet Healthcare Partners Accredited Partnership III,LP (5-9,99%)
1 more
CVR · view owners
Thomas Michael Moestrup
Board: Mads Christian Olesen (chair) and 2 members
CVR · view management
Active
Founded 17 October 2011
CVR · view overview
96 employees
CVR · 2026
Director registered: Thomas Michael Moestrup
CVR · 01/07/2018
View the full event history
CHR. OLESEN SYNTHESIS A/S is a Danish company of the type Aktieselskab based in Hvidovre, founded in 2011. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The management consists of Thomas Michael Moestrup. The board consists of Mads Christian Olesen (chair), James Charles Gale and Tibor Simon. The company is owned by CHR. OLESEN A/S, Signet Healthcare Partners Accredited Partnership III,LP and Signet Healthcare Partners QP Partnership III, LP. The company has 96 employees (2026). In 2025, the company reported a gross profit of EUR 6,958,825 and a net result of EUR -2,299,046 compared with EUR 7,391,800 the year before. Equity in the 2025 report amounted to EUR -9,489,900.
Source: annual report 2025, Danish Business Authority
The financial health of CHR. OLESEN SYNTHESIS A/S shows significant volatility, with a concerning trend in profitability and equity. Gross profit peaked at 10,567,701 EUR in 2024 but has since declined to 6,958,825 EUR in 2025, while the company reported a loss of 2,299,046 EUR in the latest fiscal year. Equity remains negative, deteriorating from -7,190,854 EUR in 2024 to -9,489,900 EUR in 2025, indicating increasing financial strain. The company's position within the pharmaceutical raw materials industry is precarious, as it struggles with profitability and mounting debt, which could hinder its growth potential moving forward.
AI-generated summary · Generated 13/08/2026
Selskabets formål er produktion af aktive pharmaceutiske ingredienser samt hermed beslægtet virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 7 mio. EUR | -2.3 mio. EUR | 24.4 mio. EUR | -9.5 mio. EUR | 79 | |
| 202401/01/2024 – 31/12/2024 | 10.6 mio. EUR | 7.4 mio. EUR | 22 mio. EUR | -7.2 mio. EUR | 55 | |
| 202301/01/2023 – 31/12/2023 | 5.4 mio. EUR | -1.5 mio. EUR | 14.9 mio. EUR | -14.6 mio. EUR | 50 | |
| 202201/01/2022 – 31/12/2022 | 3.6 mio. EUR | -2.2 mio. EUR | 12.5 mio. EUR | -13.1 mio. EUR | 49 | |
| 202101/01/2021 – 31/12/2021 | -47 t. EUR | -4.6 mio. EUR | 10.5 mio. EUR | -10.9 mio. EUR | 50 | |
| 202001/01/2020 – 31/12/2020 | 1.4 mio. EUR | -3.3 mio. EUR | 12.3 mio. EUR | -6.3 mio. EUR | 49 | |
| 201901/01/2019 – 31/12/2019 | 1.7 mio. EUR | -3.1 mio. EUR | 11.2 mio. EUR | -3 mio. EUR | 49 | |
| 201801/10/2017 – 30/09/2018 | 267 t. EUR | -3.6 mio. EUR | 10.9 mio. EUR | 1.5 mio. EUR | 43 | |
| 201701/10/2016 – 30/09/2017 | 1.2 mio. EUR | -2.3 mio. EUR | 10.2 mio. EUR | 5.1 mio. EUR | 42 | |
| 201601/10/2015 – 30/09/2016 | -502 t. EUR | -3.2 mio. EUR | 10.4 mio. EUR | 7.4 mio. EUR | - | |
| 201501/10/2014 – 30/09/2015 | 742 t. EUR | -1.4 mio. EUR | 12.3 mio. EUR | 10.6 mio. EUR | - | |
| 201401/10/2013 – 30/09/2014 | -166 t. EUR | -2 mio. EUR | 4.9 mio. EUR | -4.6 mio. EUR | - | |
| 201301/10/2012 – 30/09/2013 | -85 EUR | -1.5 mio. EUR | 3.7 mio. EUR | -2.6 mio. EUR | - | |
| 201217/10/2011 – 30/09/2012 | -934 t. | -1.6 mio. | 2.1 mio. | -1.2 mio. | - |
Compared to 25 companies in Fremstilling af farmaceutiske råvarer
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
1 properties
Upgrade to Pro to see addresses, building data and ownership details
Property report (PDF)
The entire property portfolio in one report: areas, usage, energy labels, flood exposure, planning zone and local plans.
See an example report (PDF)Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorThe CVR number of CHR. OLESEN SYNTHESIS A/S is 33964870.
CHR. OLESEN SYNTHESIS A/S is owned by CHR. OLESEN A/S, Signet Healthcare Partners Accredited Partnership III,LP and Signet Healthcare Partners QP Partnership III, LP.
The management of CHR. OLESEN SYNTHESIS A/S consists of Thomas Michael Moestrup.
The board of CHR. OLESEN SYNTHESIS A/S consists of Mads Christian Olesen, James Charles Gale and Tibor Simon, with Mads Christian Olesen as chair.
In 2025, CHR. OLESEN SYNTHESIS A/S reported a gross profit of EUR 6,958,825.
CHR. OLESEN SYNTHESIS A/S had 96 employees in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
CHR. OLESEN SYNTHESIS A/S has published its annual report for 2025. Gross profit came to DKK 6,958,825, and the net result was DKK -2,299,046.
CHR. OLESEN SYNTHESIS A/S has published its annual report for 2024. Gross profit came to DKK 10,567,701, and the net result was DKK 7,391,800.
CHR. OLESEN SYNTHESIS A/S has published its annual report for 2023. Gross profit came to DKK 5,423,186, and the net result was DKK -1,522,419.
CHR. OLESEN SYNTHESIS A/S has published its annual report for 2022. Gross profit came to DKK 3,644,323, and the net result was DKK -2,188,514.
CHR. OLESEN SYNTHESIS A/S has published its annual report for 2021. Gross profit came to DKK -46,551, and the net result was DKK -4,556,136.
CHR. OLESEN SYNTHESIS A/S has published its annual report for 2020. Gross profit came to DKK 1,381,141, and the net result was DKK -3,272,955.
CHR. OLESEN SYNTHESIS A/S has published its annual report for 2019. Gross profit came to DKK 1,732,625, and the net result was DKK -3,060,469.
CHR. OLESEN SYNTHESIS A/S has published its interim report for the period October 1, 2018 – December 31, 2018.
CHR. OLESEN SYNTHESIS A/S has published its annual report for 2018. Gross profit came to DKK 267,228, and the net result was DKK -3,616,057.
As of July 1, 2018, Thomas Michael Moestrup is registered as adm. dir. of CHR. OLESEN SYNTHESIS A/S.
As of June 30, 2018, Terje Aarbogh has left the board of directors of CHR. OLESEN SYNTHESIS A/S.
As of June 30, 2018, Terje Aarbogh has stepped down as director of CHR. OLESEN SYNTHESIS A/S.
As of May 31, 2018, Jørgen Damsbo Andersen has left the board of directors of CHR. OLESEN SYNTHESIS A/S.
CHR. OLESEN SYNTHESIS A/S has published its annual report for 2017. Gross profit came to DKK 1,201,543, and the net result was DKK -2,306,202.
CHR. OLESEN SYNTHESIS A/S has published its annual report for 2016. Gross profit came to DKK -501,614, and the net result was DKK -3,223,972.
As of June 15, 2016, Jørgen Damsbo Andersen has joined the board of directors of CHR. OLESEN SYNTHESIS A/S.
CHR. OLESEN SYNTHESIS A/S has published its annual report for 2015. Gross profit came to DKK 742,286, and the net result was DKK -1,386,267.
As of October 1, 2015, Tibor Simon has joined the board of directors of CHR. OLESEN SYNTHESIS A/S.
As of September 30, 2015, James Charles Gale has joined the board of directors of CHR. OLESEN SYNTHESIS A/S.
As of September 30, 2015, Svend Aage Johansen has left the board of directors of CHR. OLESEN SYNTHESIS A/S.
As of September 30, 2015, CHR. OLESEN A/S is registered as an owner of CHR. OLESEN SYNTHESIS A/S with an ownership share of 50%.
As of September 30, 2015, is registered as an owner of CHR. OLESEN SYNTHESIS A/S with an ownership share of 5%.
As of September 30, 2015, is registered as an owner of CHR. OLESEN SYNTHESIS A/S with an ownership share of 33%.
CHR. OLESEN SYNTHESIS A/S has published its annual report for 2014. Gross profit came to DKK -165,799, and the net result was DKK -2,004,972.
CHR. OLESEN SYNTHESIS A/S has published its annual report for 2013. Gross profit came to DKK -85, and the net result was DKK -1,455,185.
CHR. OLESEN SYNTHESIS A/S has published its annual report for 2012. Gross profit came to DKK -934,374, and the net result was DKK -1,636,018.
As of May 1, 2012, Terje Aarbogh has joined the board of directors of CHR. OLESEN SYNTHESIS A/S.
As of May 1, 2012, Allan Ardensø has left the board of directors of CHR. OLESEN SYNTHESIS A/S.
As of January 1, 2012, Terje Aarbogh is registered as director of CHR. OLESEN SYNTHESIS A/S.
As of January 1, 2012, Svend Aage Johansen has stepped down as director of CHR. OLESEN SYNTHESIS A/S.
As of October 18, 2011, Svend Aage Johansen is registered as director of CHR. OLESEN SYNTHESIS A/S.
As of October 18, 2011, Terje Aarbogh has stepped down as director of CHR. OLESEN SYNTHESIS A/S.
As of October 17, 2011, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of CHR. OLESEN SYNTHESIS A/S.
As of October 17, 2011, Svend Aage Johansen has joined the board of directors of CHR. OLESEN SYNTHESIS A/S.
As of October 17, 2011, Allan Ardensø has joined the board of directors of CHR. OLESEN SYNTHESIS A/S.
As of October 17, 2011, Mads Christian Olesen has joined the board of directors of CHR. OLESEN SYNTHESIS A/S.
As of October 17, 2011, Terje Aarbogh is registered as director of CHR. OLESEN SYNTHESIS A/S.
CHR. OLESEN SYNTHESIS A/S was founded on October 17, 2011.
